Vnitr Lek 2011, 57(11):888-890

Current and future options for treatment of osteoporosis

J. Blahoš
Oddělení klinické endokrinologie a Osteocentrum ÚVN Praha, vedoucí prof. MUDr. Jaroslav Blahoš, DrSc.

The author describes actual and perspective treatment of osteoporosis. Basic treatment consists in calcium, vitamin D, physical activity, restriction of risk factors and prevention of falls. Actual treatment includes antiresorptive drugs (calcitonin, bisphosphonates, estrogens and SERM) and denosumab. Perspective emerging drugs are also mentioned.

Keywords: osteoporosis; actual and emerging treatment

Received: September 26, 2011; Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Blahoš J. Current and future options for treatment of osteoporosis. Vnitr Lek. 2011;57(11):888-890.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Blahoš J. Treatment and prevention of osteoporosis. Wien Med Wochenschr 2007; 157: 589-592. Go to original source... Go to PubMed...
    2. Vyskočil V. Osteoporóza a ostatní nejčastější metabolická onemocnění skeletu. Praha: Galén 2009.
    3. Skácelová S. Denosumab. Remedia 2011; 3: 230-237.
    4. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276-1287. Go to original source... Go to PubMed...
    5. Stroup GB, Lark MW, Veber DF et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2011; 16: 1739-1746. Go to original source... Go to PubMed...
    6. Pathi D, Stouch B, Jang G et al. Antisklerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 2007; 22: 537-545. Go to PubMed...
    7. Cirmanová V, Stárka L. Sklerostin - nový regulační marker kostního obratu a klíčový cíl v terapii osteoporózy. Osteol Bull 2011; 1: 16-19.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.